FIELD: chemistry; pharmacology.
SUBSTANCE: present invention relates to biotechnology. The described molecules of antibodies, having specificity in relation to human CD22, containing at least one CDR obtained from mouse monoclonal antibodies. Also discovered is a CDR-grafted antibody, in which at least one of the CDR is a modified CDR. The DNA sequence of the coding strand of the antibody molecule is described. Vectors are offered which contain the described DNA sequence, transformed host-cells, containing the offered vectors. The administration of antibody molecules during the treatment of diseases, mediated by cells expressing CD22 has been discovered.
EFFECT: obtaining antibodies, which posses a high affinity to CD22 and immunogenic inferiority to humans.
28 cl, 16 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES "CALIHEAMICIN DERIVATIVE-CARRIER" | 2003 |
|
RU2422157C2 |
| ANTIBODY MOLECULES POSSESSING SPECIFICITY WITH RESPECT TO HUMAN TUMOR NECROSIS FACTOR-ALPHA AND THEIR USING | 2001 |
|
RU2303604C2 |
| CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
| CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2011 |
|
RU2602878C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| HUMANISED ANTI-FACTOR D ANTIBODIES AND USE THEREOF | 2007 |
|
RU2474589C2 |
| HUMANISED ANTI-FACTOR D ANTIBODIES AND APPLICATIONS THEREOF | 2012 |
|
RU2678802C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2640252C2 |
